Clifford Capital Partners LLC Sells 15,998 Shares of Becton, Dickinson and Company $BDX

Clifford Capital Partners LLC lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.0% in the fourth quarter, HoldingsChannel reports. The fund owned 107,312 shares of the medical instruments supplier’s stock after selling 15,998 shares during the period. Becton, Dickinson and Company accounts for approximately 3.5% of Clifford Capital Partners LLC’s investment portfolio, making the stock its 11th largest holding. Clifford Capital Partners LLC’s holdings in Becton, Dickinson and Company were worth $20,826,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Skba Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 1,619.9% during the third quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after purchasing an additional 54,170 shares during the period. Graybill Wealth Management LTD. boosted its stake in shares of Becton, Dickinson and Company by 47.3% in the third quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after buying an additional 8,859 shares during the period. Danske Bank A S bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $34,596,000. Finally, Berkeley Capital Partners LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $1,592,000. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent research reports. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Piper Sandler cut their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Argus cut their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Bank of America cut their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Finally, Evercore boosted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $181.00.

Becton, Dickinson and Company Stock Down 2.5%

NYSE BDX opened at $141.58 on Thursday. The business has a fifty day moving average price of $149.37 and a two-hundred day moving average price of $172.86. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The stock has a market capitalization of $39.01 billion, a PE ratio of 35.84, a PEG ratio of 10.28 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period in the prior year, the company earned $3.35 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 3.0%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the completion of the sale, the executive vice president directly owned 14,272 shares in the company, valued at $2,161,922.56. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock valued at $593,434 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.